tirzepatide surmount 2 for the Maintenance of Body Weight Reduction: Rationale, Design, and Baseline Characteristics of SURMOUNT‐MAINTAIN - Horn - 2025 - Obesity Tirzepatide Delivers in SURMOUNT-2 -

Daily use means you interact with the vial every night, so maintaining sterile technique with each draw becomes habitual

Whether you're considering stopping due to side effects, cost concerns, or because you've reached your health goals, understanding what happens during this period can help you maintain your progress and prepare for the changes ahead

Survodutide is another dual agonist targeting GLP-1 and glucagon receptors (without GIP), currently in Phase 3 trials

To stack safely requires medical oversight

41,42 In addition, lipid metabolism, inflammation, fibrosis, and cell death interact with each other, and the respective roles of GLP-1RA therein collectively comprise its therapeutic pathway in MASLD